Kallistatin modulates immune cells and confers anti-inflammatory response to protect mice from group a streptococcal infection

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5366-5372

  Lu, Shiou Ling ^a   Tsai, Chiau Yuang ^a   Luo, Yueh Hsia ^a   Kuo, Chih Feng ^b   Lin, Wei Chieh ^c   Chang, Yu Tzu ^c   Wu, Jiunn Jong ^a,d   Chuang, Woei Jer ^a,d   Liu, Ching Chuan ^a,d   Chao, Lee ^e   Chao, Julie ^e   Lin, Yee Shin ^a,d  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; KALLISTATIN; REACTIVE OXYGEN METABOLITE; SERINE PROTEINASE INHIBITOR; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL CLEARANCE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; CELL INFILTRATION; CELL VIABILITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG LIVER LEVEL; DRUG TISSUE LEVEL; GROUP A STREPTOCOCCAL INFECTION; HYDRODYNAMICS; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFECTION PREVENTION; INFLAMMATION; INOCULATION; LIVER INJURY; MOUSE; NEUTROPHIL; NONHUMAN; PLASMID; PRIORITY JOURNAL; SKIN DEFECT; SURVIVAL RATE; TRANSIENT EXPRESSION; TREATMENT OUTCOME;

ANIMALS; GENE EXPRESSION; HUMANS; IMMUNOMODULATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; MICE; NEUTROPHILS; SERPINS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; SURVIVAL ANALYSIS; TRANSGENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885938281     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00322-13     Document Type: Article

References (44)

1. Cole JN, Barnett TC, Nizet V, Walker MJ. 2011. Molecular insight into invasive group A streptococcal disease. Nat. Rev. Microbiol. 9:724-736.
2. O'Connell D. 2006. Bacterial pathogenesis: Triggering GAS invasive disease. Nat. Rev. Microbiol. 4:644-645.
3. Steer AC, Lamagni T, Curtis N, Carapetis JR. 2012. Invasive group A streptococcal disease: Epidemiology, pathogenesis and management. Drugs 72:1213-1227.
4. Olsen RJ, Musser JM. 2010. Molecular pathogenesis of necrotizing fasciitis. Annu. Rev. Pathol. 5:1-31.
5. Bisno AL, Brito MO, Collins CM. 2003. Molecular basis of group A streptococcal virulence. Lancet Infect. Dis. 3:191-200.
6. Chiappini N, Seubert A, Telford JL, Grandi G, Serruto D, Margarit I, Janulczyk R. 2012. Streptococcus pyogenes SpyCEP influences hostpathogen interactions during infection in a murine air pouch model. PLoS One 7:e40411. doi:10.1371/journal.pone.0040411.
7. Hung CH, Tsao N, Zeng YF, Lu SL, Chuan CN, Lin YS, Wu JJ, Kuo CF. 2012. Synergistic effects of streptolysin S and streptococcal pyrogenic exotoxin B on the mouse model of group A streptococcal infection. Med. Microbiol. Immunol. 201:357-369.
8. Thomas CL, Lee SW. 2012. Knowing is half the battle: Targeting virulence factors of group A streptococcus for vaccine and therapeutics. Curr. Drug Targets 13:308-322.
9. Musser JM, DeLeo FR. 2005. Toward a genome-wide systems biology analysis of host-pathogen interactions in group A streptococcus. Am. J. Pathol. 167:1461-1472.
10. Currie BJ. 2006. Group A streptococcal infections of the skin: Molecular advances but limited therapeutic progress. Curr. Opin. Infect. Dis. 19: 132-138.
11. Steer AC, Batzloff MR, Mulholland K, Carapetis JR. 2009. Group A streptococcal vaccines: Facts versus fantasy. Curr. Opin. Infect. Dis. 22: 544-552.
12. Chao J, Tillman DM, Wang MY, Margolius HS, Chao L. 1986. Identification of a new tissue-kallikrein-binding protein. Biochem. J. 239:325-331.
13. Chao J, Schmaier A, Chen LM, Yang Z, Chao L. 1996. Kallistatin, a novel human tissue kallikrein inhibitor: Levels in body fluids, blood cells, and tissues in health and disease. J. Lab. Clin. Med. 127:612-620.
14. Chao J, Stallone JN, Liang YM, Chen LM, Chao L. 1997. Kallistatin is a potent new vasodilator. J. Clin. Invest. 100:11-17.
15. Miao RQ, Murakami H, Song Q, Chao L, Chao J. 2000. Kallistatin stimulates vascular smooth muscle cell proliferation and migration in vitro and neointima formation in balloon-injured rat artery. Circ. Res. 86:418-424.
16. Miao RQ, Agata J, Chao L, Chao J. 2002. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 100:3245-3252.
17. Shiau AL, Teo ML, Chen SY, Wang CR, Hsieh JL, Chang MY, Chang CJ, Chao J, Chao L, Wu CL, Lee CH. 2010. Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin. BMC Cancer 10:245.
18. Chao J, Yin H, Yao YY, Shen B, Smith RS, Chao L. 2006. Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum. Gene Ther. 17:1201-1213.
19. Shen B, Gao L, Hsu YT, Bledsoe G, Hagiwara M, Chao L, Chao J. 2010. Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. Am. J. Physiol. Heart Circ. Physiol. 299:1419-1427.
20. Liu Y, Bledsoe G, Hagiwara M, Shen B, Chao L, Chao J. 2012. Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. Am. J. Physiol. Renal Physiol. 303:1230-1238.
21. Stadnicki A, Mazurek U, Plewka D, Wilczok T. 2003. Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease. Int. Immunopharmacol. 3:939-944.
22. Zhu H, Chao J, Kotak I, Guo D, Parikh SJ, Bhagatwala J, Dong Y, Patel SY, Houk C, Chao L, Dong Y. 2013. Plasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescents. Metabolism 62:642-646.
23. Wang CR, Chen SY, Wu CL, Liu MF, Jin YT, Chao L, Chao J. 2005. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum. 52:1319-1324.
24. Yin H, Gao L, Shen B, Chao L, Chao J. 2010. Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-induced nuclear factor B activation. Hypertension 56:260-267.
25. Chen LM, Chao L, Chao J. 1997. Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. Life Sci. 60:1431-1435.
26. Frank AJ, Sheu CC, Zhao Y, Chen F, Su L, Gong MN, Bajwa E, Thompson BT, Christiani DC. 2012. BCL2 genetic variants are associated with acute kidney injury in septic shock. Crit. Care Med. 40:2116-2123.
27. Kuo CF, Wu JJ, Lin KY, Tsai PJ, Lee SC, Jin YT, Lei HY, Lin YS. 1998. Role of streptococcal pyrogenic exotoxin B in the mouse model of group A streptococcal infection. Infect. Immun. 66:3931-3935.
28. Kuo CF, Luo YH, Lin HY, Huang KJ, Wu JJ, Lei HY, Lin MT, Chuang WJ, Liu CC, Jin YT, Lin YS. 2004. Histopathologic changes in kidney and liver correlate with streptococcal pyrogenic exotoxin B production in the mouse model of group A streptococcal infection. Microb. Pathog. 36:273-285.
29. Kuo CF, Chen CC, Luo YH, Huang RY, Chuang WJ, Sheu CC, Lin YS. 2005. Cordyceps sinensis mycelium protects mice from group A streptococcal infection. J. Med. Microbiol. 54:795-802.
30. Li MH, Luo YH, Lin CF, Chang YT, Lu SL, Kuo CF, Hong JS, Lin YS. 2011. Dextromethorphan efficiently increases bactericidal activity, attenuates inflammatory responses and prevents group A streptococcal sepsis. Antimicrob. Agents Chemother. 55:967-973.
31. Liu F, Song YK, Liu D. 1999. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6:1258-1266.
32. Zhang G, Gao X, Song YK, Vollmer R, Stolz DB, Gasiorowski JZ, Dean DA, Liu D. 2004. Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther. 11:675-682.
33. Xiong W, Tang CQ, Zhou GX, Chao L, Chao J. 1992. In vivo catabolism of human kallikrein-binding protein and its complex with tissue kallikrein. J. Lab. Clin. Med. 119:514-521.
34. Kobayashi SD, Braughton KR, Whitney AR, Voyich JM, Schwan TG, Musser JM, DeLeo FR. 2003. Bacterial pathogens modulate an apoptosis differentiation program in human neutrophils. Proc. Natl. Acad. Sci. U. S. A. 100:10948-10953.
35. Voyich JM, Musser JM, DeLeo FR. 2004. Streptococcus pyogenes and human neutrophils: A paradigm for evasion of innate host defense by bacterial pathogens. Microbes Infect. 6:1117-1123.
36. Miller RA, Britigan BE. 1997. Role of oxidants in microbial pathophysiology. Clin. Microbiol. Rev. 10:1-18.
37. Lukaszewicz AC, Gontier G, Faivre V, Ouanounou I, Payen D. 2012. Elevated production of radical oxygen species by polymorphonuclear neutrophils in cerebrospinal fluid infection. Ann. Intensive Care 2:10.
38. Gao G, Shao C, Zhang SX, Dudley A, Fant J, Ma JX. 2003. Kallikreinbinding protein inhibits retinal neovascularization and decreases vascular leakage. Diabetologia 46:689-698.
39. Stevens DL. 2000. Streptococcal toxin shock syndrome associated with necrotizing fasciitis. Annu. Rev. Med. 51:271-288.
40. Hidalgo-Grass C, Mishalian I, Dan-Goor M, Belotserkovsky I, Eran Y, Nizet V, Peled A, Hanski E. 2006. A streptococcal protease that degrades CXC chemokines and impairs bacterial clearance from infected tissues. EMBO J. 25:4628-4637.
41. Medina E, Anders D, Chhatwal GS. 2002. Induction of NF-B nuclear translocation in human respiratory epithelial cells by group A streptococci. Microb. Pathog. 33:307-313.
42. Tsai PJ, Chen YH, Hsueh CH, Hsieh CH, Liu YH, Wu JJ, Tsou CC. 2006. Streptococcus pyogenes induces epithelial inflammatory responses through NF-B/MAPK signaling pathways. Microbes Infect. 8:1440-1449.
43. Tsao N, Lin TY, Chou CK, Wu JJ, Lin YS, Lei HY. 2001. Inhibition of group A streptococcus infection by carboxyfullerene. Antimicrob. Agents Chemother. 45:1788-1793.
44. Lin WC, Lu SL, Lin CF, Chen CW, Chao L, Chao J, Lin YS. 8 February 2013. Plasma kallistatin levels in patients with severe community-Acquired pneumonia. Crit. Care 17:R27. [Epub ahead of print.] doi:10.1186/cc12507.